论文部分内容阅读
Lyotropic liquid crystalline phases are currently arousing increasing concern due to their strong capabilities to protect hydrophilic, lipophilic and amphiphilic molecules from hydrolysis and oxidation.Recently, the topical treatment of chronic wounds, such as venous,diabetic and pressure ulcers have become a major clinical challenge.The purpose of this study was to develop recombinant human epidermal growth factor (rhEGF) loaded liquid crystalline precursor for the effective treatment of chronic wounds.Liquid crystalline precursor composed of glycerol monooleate (GMO), ethanol (EtOH) and water was developed and characterized by polarized fight microscopy, small angle X-ray scattering (SAXS).The optimized formulation (GMO/EtOH/water, 72∶ 18∶ 10, w/w/w) loaded with rhEGF showed a strong ability to form a cubic liquid crystalline gel in situ with small amounts of water absorption in the extremely short time.The developed formulation was found to be able to sustain the drug release for more than 10 days and was suitable for topical administration for the treatment of chronic wounds.